May 2012 Private and Confidential This document is intended - - PowerPoint PPT Presentation

▶
may 2012
SMART_READER_LITE
LIVE PREVIEW

May 2012 Private and Confidential This document is intended - - PowerPoint PPT Presentation

Apr 19, 2023 251 likes •420 views

May 2012 Private and Confidential This document is intended exclusively for the confidential use of its recipients, based on their recognition and acceptance of the confidentiality of the same. The reproduction of this information, in whole or in

slide-1
SLIDE 1

Confidential: For intended recipient use only 1 Confidential: For intended recipient use only

Private and Confidential This document is intended exclusively for the confidential use of its recipients, based on their recognition and acceptance of the confidentiality of the same. The reproduction of this information, in whole or in part, is totally forbidden, as well as its communication to third parties without the prior express consent of the issuer.

May 2012

slide-2
SLIDE 2

Confidential: For intended recipient use only 2 Confidential: For intended recipient use only

INDEX

  • 1. COMPANY OVERVIEW
  • 2. AB-FUNCTIONAL INGREDIENTS
  • 3. AB-GENOTYPING
  • 4. QUANTUM - R&D SERVICES
slide-3
SLIDE 3

Confidential: For intended recipient use only 3 Confidential: For intended recipient use only

2008

  • 1st Financing Round:

Business Angels – €1M

AB-BIOTICS strives to improve health by developing products and providing services that help support healthy living and prevent disease. AB-BIOTICS aspires to set a standard in the European biotechnology industry for both value and profitability.

COMPANY OVERVIEW - OUR MISSION & VALUES

2004

  • Company Founded at

Universitat Autonoma Barcelona

2011

  • Capital Increase – €4,3M
  • Acquisition of Quantum Experimental
  • €5,0M Turnover

Mission Vision

2012

  • International Expansion

(US, BR)

2010

  • Financing Round: Public

Trading €3,5M

  • €3,6M Turnover

History

slide-4
SLIDE 4

Confidential: For intended recipient use only 4 Confidential: For intended recipient use only

Project Management R&D projects for companies. Main clients belong to the Food Functional and Food supplements. Quantum Experimental :CRO, regulatory, analysis, and industrial. Historic 5 years in operation and constant growth. In company R&D for development of functional ingredients, mainly probiotics for application in functional foods and food supplements. Company subsidiary dedicated to the development of advanced genetic tools for pharmacogenetics (SNP, CNV) The company has appropriate human and technical resources for conducting genetic analysis.

Focus on areas with clearest competitive advantage:

AB-Functional Ingredients & AB-Genotyping

A balanced risk portfolio:

PROFIT POTENTIAL RISK

COMPANY OVERVIEW – BUSINESS AREAS

+ +

  • &

R&D SERVICES

slide-5
SLIDE 5

Confidential: For intended recipient use only 5 Confidential: For intended recipient use only

AB-FUNCTIONAL INGREDIENTS

  • 1. COMPANY OVERVIEW
  • 2. AB-FUNCTIONAL INGREDIENTS
  • 3. AB-GENOTYPING
  • 4. QUANTUM - R&D SERVICES
slide-6
SLIDE 6

Confidential: For intended recipient use only 6 Confidential: For intended recipient use only

AB-FUNCTIONAL INGREDIENTS - MARKET OVERVIEW

Competitive Advantage

AB-Biotics strain bank has over 550 different strains with highly unique characteristics.

Probiotics have been a major growth driver within FF food, while probiotic supplements have been among the most dynamic products within the global VDS market. * AB-Biotic´s clear strain definition, unique source hypothesis, and large strain bank provides a clear competitive differentiation in probiotics.

Market Projections

FF= Fortified/Functional, VDS=Vitamin, Dietary, Supplement* *Source: Euromonitor Oct 2010

slide-7
SLIDE 7

Confidential: For intended recipient use only 7 Confidential: For intended recipient use only

AB-FUNCTIONAL INGREDIENTS - AB-LIFE

Cardiovascular disease is the world´s leading cause of death (49% in Spain).* High cholesterol increases risk of cardiovascular disease. Current treatments only target one of the two types of cholesterol (endogenous, dietary). Additionally, adverse hepatic and intestinal reactions arise at high doses. Patented product in PCT phase of IP protection entering national phase in the next 6-8 months. AB-LIFE, a probiotic, significantly lowers both types of cholesterol and has no adverse reactions at high doses. It can be delivered as food ingredient or supplement.

The Market The Product

Recent license agreements have been reached in Brazil, Spain, Hungary and Slovenia for supplements. Negotiating with MNCs for world-wide license (food).

Recent News

Spanish ** English***

  • Source: WHO 2010

**http://www.youtube.com/user/ABBIOTICS#p/a/u/2/fv3IMsqv19o *** http://www.youtube.com/user/ABBIOTICS#p/a/u/1/kkvjSCbA0X8

slide-8
SLIDE 8

Confidential: For intended recipient use only 8 Confidential: For intended recipient use only

AB-FUNCTIONAL INGREDIENTS – IBS - 3.1

IBS, characterized by abdominal pain, discomfort, bloating and altered intestinal motility and transit, and affects between 10 - 15% of the population*. Existing treatments are extremely limited by effect and carry significant side effects. Pharmacological treatment is limited in most countries. Patented product in PCT phase of IP protection, entering national phase by July 2012. IBS 3.1, a probiotic, achieves a global improvement in Quality of Life of afflicted patients, according to initial results from a multicentric clinical trial.

The Market The Product

Current clinical trials will conclude by December, and clinical trials in the US begin in Q1 2012. Presented at Biowashington 2011.

Recent News

English**

* Source: Quigley EM et al, July 2006 Aliment. Pharmacol. Ther ** http://www.youtube.com/user/ABBIOTICS#p/a/u/0/U4Gt2X_rpos

slide-9
SLIDE 9

Confidential: For intended recipient use only 9 Confidential: For intended recipient use only

AB-FUNCTIONAL INGREDIENTS - AB-FORTIS

Iron deficiency in children, whether due to diet or absorption, can lead to lower infection resistance and impaired pyschomotor and cognitive development*. Current fortification solutions have issues with iron

  • xidation, leading to a false metallic taste and lower

shelf-life stability. Patented product entering national phase of IP protection. 11 health claims approved by EFSA. AB-FORTIS can deliver 100% of the iron CDR with no

  • xidation in yoghurt, milk, or meat, and can delivered as

a food supplement.

The Market The Product

Over the next 2-12 months, examinations for national phase of protection will begin in 32 different countries. Negotiating with MNCs for world-wide license.

Recent News

*SAC = School-Age-Children

Impact

Spanish ** English ***

* Source: Kigangou, 2005, Ped. Res. 731 ** http://www.youtube.com/user/ABBIOTICS#p/a/u/0/wUx0Y1yDLxI *** http://www.youtube.com/user/ABBIOTICS#p/a/u/1/aQHRX7Lt1A8

slide-10
SLIDE 10

Confidential: For intended recipient use only 10 Confidential: For intended recipient use only

AB-GENOTYPING

  • 1. COMPANY OVERVIEW
  • 2. AB-FUNCTIONAL INGREDIENTS
  • 3. AB-GENOTYPING
  • 4. QUANTUM - R&D SERVICES
slide-11
SLIDE 11

Confidential: For intended recipient use only 11 Confidential: For intended recipient use only

Personalized Medicine and Pharmacogenetics

“It is not the analysis of disease genetic risk factors that shoes the most immediate promise for human health, but the application of genetic information to permit safer and more efficacious use of drugs.” – Caplan A., What Will Drive Genomics Over the Next 10 Years, Science 2011 “The evolution of personalized medicine will change the healthcare industry. In the process, it is likely that several “gamechangers” will emerge—aspects of new technology that will result in significant commercial or social impacts.” - DC-based research and consulting firm Social Technologies “Industry consensus is that pharmacogenomics – that is, combination diagnostic and pharmaceutical products – will be part of mainstream medicine within 10 years.” - PWC

AB-GENOTYPING - MARKET OVERVIEW

Neuropsychiatry Cancer

Neurofarmagen product launched since January 2010. % Prevalence % Inefficient Treatment Depression 10% 80% Epilepsy, Schizophrenia, Bipolar 1% 20-30% Oncofarmagen pipeline product..

slide-12
SLIDE 12

Confidential: For intended recipient use only 12 Confidential: For intended recipient use only

AB-GENOTYPING - PHARMACOGENETICS

CURRENT THERAPEUTIC MODEL PERSONALIZED MEDICINE

Increase dose drug Standard dose Dose reduction Drastic reduction in dose or drug change

Same diagnostic Same treatment

Same diagnostic + Genetic test Test benefits 1. Decreased adverse reactions 2. Safer election of drugs 3. Better treatment compliance 4. Increased probability of therapeutic success 5. Reduced costs for Health Care System

Herceptin’s Clinical Trial (Roche) Aclara Bioscience (Monogram Bioscience). Business Insights ltd.

slide-13
SLIDE 13

Confidential: For intended recipient use only 13 Confidential: For intended recipient use only

AB-GENOTYPING - NEUROFARMAGEN

Number of tested drugs 39 Quality controls 48 Number of genetic variations 98 Number of genes analyzed 53 NEUROPHARMAGENV.2.1 compiles information for a total of 39 drugs  2/3 patients significantly improves their quality of life. No side effects & higher efficacy. Fast stabilization for patients with epilepsy, clinical depression, bipolar syndrome and schizophrenia.

slide-14
SLIDE 14

Confidential: For intended recipient use only 14 Confidential: For intended recipient use only

QUANTUM AND R&D SERVICES

  • 1. COMPANY OVERVIEW
  • 2. AB-FUNCTIONAL INGREDIENTS
  • 3. AB-GENOTYPING
  • 4. QUANTUM - R&D SERVICES
slide-15
SLIDE 15

Confidential: For intended recipient use only

INDUSTRIAL

  • Industrial Development

for Health Products

  • Management Pilot

Batch Manufacturing and Industrial Lots

  • Consultancy

specialized in manufacturer selection, preparation

  • f documents and

proceedings before the Health Authorities

ANALYSIS

  • Qualitiy Control for

Food and Farma Companies

  • Pharmaceutical

development, analytical method development and stability studies (ICH) Laboratories ISO 9000:2001 Certified and AENOR

REGULATORY

  • Regulation Strategy

and Preparation of dossiers (Dietary Complements, Ingredients, Generics, Cosmetics, Medical Devices, ...)

  • Drug Master · Europe

File

  • Licenses Request,

expert reports and Pharmaco-vigilance

CRO

  • Clinical trials of dietary

supplements and foods.

  • Drug Trials (FI, FII,

FIII, FIV)

  • International Network
  • f CRO (Well CRO)
  • Consumer Tests,

Readability, and Meta- analysis Publications

Time to Market Reduction

QUANTUM EXPERIMENTAL – SERVICES PORTFOLIO